CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
具有适应性的白血病细胞经 B 细胞活化抵抗 CAR-T 细胞攻击
英文原题：Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation.
查看英文原题
Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法在B细胞恶性肿瘤的治疗中已取得显著里程碑。然而，在大量患者中，癌细胞常常能在CAR-T 细胞杀伤后存活。复发往往与抗原丢失相关。在本期中，Im及其同事报道了白血病细胞对抗CD19 CAR-T 细胞耐药的一种新机制：白血病细胞能够启用B细胞活化和生发中心反应特征，从而导致CD19转录下调并在CAR暴露后存活。参见Im等人相关文章，第1055页（5）。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable milestones in the treatment of B-cell malignancies.
However, cancer cells frequently survive CAR T-cell killing in a large cohort of patients. Relapse oftentimes is associated with antigen loss. In this issue, Im and colleagues report a new mechanism of leukemic-cell resistance to anti-CD19 CAR T cells: Leukemic cells can enable a B-cell activation and germinal center reaction signature, which causes CD19 transcriptional downregulation and survival from CAR exposure. See related article by Im et al. , p. 1055 (5).
论文信息
- 作者
- Zhao Z、Melenhorst JJ
- 单位
- Cell Therapy & Immuno-Engineering Program, Center for ImmunoTherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.United States
- 文献类型
- 社论 · 评论
- 期刊
- Cancer immunology research2022 Sep 1
- 原文标识
- PubMed 35917325 · DOI 10.1158/2326-6066.CIR-22-0543
READING GUIDES
相关资料阅读指南
了解这条资料涉及的技术、疾病或试验登记信息，再回到原始来源核实。